journal
https://read.qxmd.com/read/38659235/high-n6-methyladenosine-activated-tceal8-mrna-is-a-novel-pancreatic-cancer-marker
#1
JOURNAL ARTICLE
Tomoaki Hara, Sikun Meng, Hiromichi Sato, Shotaro Tatekawa, Kazuki Sasaki, Yu Takeda, Yoshiko Tsuji, Yasuko Arao, Ken Ofusa, Toru Kitagawa, Daisaku Yamada, Hidenori Takahashi, Shogo Kobayashi, Daisuke Motooka, Yutaka Suzuki, Sarah Rennie, Shizuka Uchida, Masaki Mori, Kazuhiko Ogawa, Yuichiro Doki, Hidetoshi Eguchi, Hideshi Ishii
N6-methyladenosine (m6A) is an RNA modification involved in RNA processing and widely found in transcripts. In cancer cells, m6A is upregulated, contributing to their malignant transformation. In this study, we analyzed gene expression and m6A modification in cancer tissues, ducts, and acinar cells derived from pancreatic cancer patients using MeRIP-seq. We found that dozens of RNAs highly modified by m6A were detected in cancer tissues compared with ducts and acinar cells. Among them, the m6A-activated mRNA TCEAL8 was observed, for the first time, as a potential marker gene in pancreatic cancer...
April 24, 2024: Cancer Science
https://read.qxmd.com/read/38655663/the-lat1-inhibitor-jph203-suppresses-the-growth-of-castration-resistant-prostate-cancer-through-a-cd24-mediated-mechanism
#2
JOURNAL ARTICLE
Shinpei Saito, Keisuke Ando, Shinichi Sakamoto, Minhui Xu, Yasutaka Yamada, Junryo Rii, Sanji Kanaoka, Jiaxing Wei, Xue Zhao, Sangjon Pae, Manato Kanesaka, Yusuke Goto, Tomokazu Sazuka, Yusuke Imamura, Yoshie Reien, Norie Hamaguchi-Suzuki, Shota Saito, Yuri Hirayama, Hirofumi Hashimoto, Yoshikatsu Kanai, Tomohiko Ichikawa, Naohiko Anzai
L-type amino acid transporter 1 (LAT1) is specifically expressed in many malignancies, contributes to the transport of essential amino acids, such as leucine, and regulates the mammalian target of rapamycin (mTOR) signaling pathway. We investigated the expression profile and functional role of LAT1 in prostate cancer using JPH203, a specific inhibitor of LAT1. LAT1 was highly expressed in castration-resistant prostate cancer (CRPC) cells, including C4-2 and PC-3 cells, but its expression level was low in castration-sensitive LNCaP cells...
April 24, 2024: Cancer Science
https://read.qxmd.com/read/38655660/microwave-ablation-combined-with-pd-l1-blockade-synergistically-promotes-cxcl9-mediated-antitumor-immunity
#3
JOURNAL ARTICLE
Ningning He, Hao Huang, Shaoxian Wu, Weipeng Ji, Yicheng Tai, Ruicheng Gao, Yingting Liu, Yungang Liu, Lujun Chen, Dawei Zhu, Xiao Zheng, Jingting Jiang
Although microwave ablation (MWA) is an important curative therapy in colorectal cancer liver metastasis, recurrence still occurs clinically. Our previous studies have shown that the expression of programmed cell death 1 ligand 1 (PD-L1) is upregulated following MWA, suggesting that MWA combined with anti-PD-L1 treatment can serve as a promising clinical therapeutic strategy against cancer. Using MWA-treated preclinical mice models, MWA combined with αPD-L1 treatment decreased tumor growth and prolonged overall survival (OS)...
April 24, 2024: Cancer Science
https://read.qxmd.com/read/38651282/usp3-key-deubiquitylation-enzyme-in-human-diseases
#4
REVIEW
Hongyan Zhang, Wenjing Liu, Yingying Wu, Ceshi Chen
Ubiquitination and deubiquitylation are pivotal posttranslational modifications essential for regulating cellular protein homeostasis and are implicated in the development of human diseases. Ubiquitin-specific protease 3 (USP3), a member of the ubiquitin-specific protease family, serves as a key deubiquitylation enzyme, playing a critical role in diverse cellular processes including the DNA damage response, cell cycle regulation, carcinogenesis, tumor cell proliferation, migration, and invasion. Despite notable research efforts, our current understanding of the intricate and context-dependent regulatory networks governing USP3 remains incomplete...
April 23, 2024: Cancer Science
https://read.qxmd.com/read/38651239/adaptive-use-of-error-prone-dna-polymerases-provides-flexibility-in-genome-replication-during-tumorigenesis
#5
REVIEW
Lewis J Bainbridge, Yasukazu Daigaku
Human cells possess many different polymerase enzymes, which collaborate in conducting DNA replication and genome maintenance to ensure faithful duplication of genetic material. Each polymerase performs a specialized role, together providing a balance of accuracy and flexibility to the replication process. Perturbed replication increases the requirement for flexibility to ensure duplication of the entire genome. Flexibility is provided via the use of error-prone polymerases, which maintain the progression of challenged DNA replication at the expense of mutagenesis, an enabling characteristic of cancer...
April 23, 2024: Cancer Science
https://read.qxmd.com/read/38641866/senescence-and-senolysis-in-cancer-the-latest-findings
#6
REVIEW
Yoshimi Imawari, Makoto Nakanishi
Aging is a life phenomenon that occurs in most living organisms and is a major risk factor for many diseases, including cancer. Cellular senescence is a cellular trait induced by various genomic and epigenetic stresses. Senescent cells are characterized by irreversible cell growth arrest and excessive secretion of inflammatory cytokines (senescence-associated secretory phenotypes, SASP). Chronic tissue microinflammation induced by SASP contributes to the pathogenesis of a variety of age-related diseases, including cancer...
April 19, 2024: Cancer Science
https://read.qxmd.com/read/38638055/efficacy-and-biomarker-analysis-of-second-line-nab-paclitaxel-plus-sintilimab-in-patients-with-advanced-biliary-tract-cancer
#7
JOURNAL ARTICLE
Xiaofen Li, Nan Zhou, Yu Yang, Zijian Lu, Hongfeng Gou
Biliary tract cancer (BTC) is a highly aggressive malignancy with limited second-line therapy. We conducted this phase 2 trial to evaluate the efficacy and safety of second-line nab-paclitaxel plus sintilimab in advanced BTC. Histologically confirmed advanced BTC patients with documented disease progression after first-line chemotherapy were enrolled. Subjects received nab-paclitaxel 125 mg/m2 on days 1 and 8 plus sintilimab 200 mg on day 1, administered every 3 weeks. The primary end point was the objective response rate (ORR)...
April 18, 2024: Cancer Science
https://read.qxmd.com/read/38634426/combination-of-high-anti-ski-and-low-anti-tmed5-antibody-levels-is-preferable-prognostic-factor-in-esophageal-carcinoma
#8
JOURNAL ARTICLE
Masaaki Ito, Satoshi Yajima, Takashi Suzuki, Yoko Oshima, Tatsuki Nanami, Makoto Sumazaki, Fumiaki Shiratori, Hirotaka Takizawa, Shu-Yang Li, Bo-Shi Zhang, Yoichi Yoshida, Tomoo Matsutani, Takaki Hiwasa, Hideaki Shimada
Given that esophageal cancer is highly malignant, the discovery of novel prognostic markers is eagerly awaited. We performed serological identification of antigens by recombinant cDNA expression cloning (SEREX) and identified SKI proto-oncogene protein and transmembrane p24 trafficking protein 5 (TMED5) as antigens recognized by serum IgG antibodies in patients with esophageal carcinoma. SKI and TMED5 proteins were expressed in Escherichia coli, purified by affinity chromatography, and used as antigens. The serum anti-SKI antibody (s-SKI-Ab) and anti-TMED5 antibody (s-TMED5-Ab) levels were significantly higher in 192 patients with esophageal carcinoma than in 96 healthy donors...
April 18, 2024: Cancer Science
https://read.qxmd.com/read/38623968/ezh2-suppresses-ferroptosis-in-hepatocellular-carcinoma-and-reduces-sorafenib-sensitivity-through-epigenetic-regulation-of-tfr2
#9
JOURNAL ARTICLE
Yongwei Lai, Xu Han, Bo Xie, Yan Xu, Zhengyi Yang, Didi Wang, Wei Li, Yaohong Xie, Wenqi Song, Xiaohong Zhang, Jia Qi Xia, Pengxia Zhang
Enhancing sensitivity to sorafenib can significantly extend the duration of resistance to it, offering substantial benefits for treating patients with hepatocellular carcinoma (HCC). However, the role of ferroptosis in influencing sorafenib sensitivity within HCC remains pivotal. The enhancer of zeste homolog 2 (EZH2) plays a significant role in promoting malignant progression in HCC, yet the relationship between ferroptosis, sorafenib sensitivity, and EZH2 is not entirely clear. Bioinformatic analysis indicates elevated EZH2 expression in HCC, predicting an unfavorable prognosis...
April 16, 2024: Cancer Science
https://read.qxmd.com/read/38623936/clonal-expansion-in-normal-tissues
#10
REVIEW
Hirona Maeda, Nobuyuki Kakiuchi
Cancer originates from a single ancestral cell that acquires a driver mutation, which confers a growth or survival advantage, followed by the acquisition of additional driver mutations by descendant cells. Recently, it has become evident that somatic cell mutations accumulate in normal tissues with aging and exposure to environmental factors, such as alcohol, smoking, and UV rays, increases the mutation rate. Clones harboring driver mutations expand with age, leading to tissue remodeling. Lineage analysis of myeloproliferative neoplasms and der(1;16)-positive breast cancer revealed that driver mutations were acquired early in our lives and that the development of cancer takes decades, unveiling the previously unknown early process of cancer development...
April 16, 2024: Cancer Science
https://read.qxmd.com/read/38613358/radiosensitizing-effect-of-a-novel-ctss-inhibitor-by-enhancing-brca1-protein-stability-in-triple-negative-breast-cancer-cells
#11
JOURNAL ARTICLE
Eun Choi, Kyung-Hwa Jeon, Hanhee Lee, Gil-Im Mun, Jeong-Ahn Kim, Jae-Ho Shin, Youngjoo Kwon, Younghwa Na, Yun-Sil Lee
Triple-negative breast cancer (TNBC) patients harboring wild-type breast cancer susceptibility gene 1 (BRCA1) account for most TNBC patients but lack adequate targeted therapeutic options. Although radiotherapy (RT) is the primary treatment modality for TNBC patients, radioresistance is one of the major challenges. RT-induced increase in cathepsin S (CTSS) causes radioresistance through suppressing BRCA1-mediated apoptosis of tumor cells, which was induced by CTSS-mediated degradation of BRCA1. Targeting CTSS may provide a novel therapeutic opportunity for TNBC patients...
April 13, 2024: Cancer Science
https://read.qxmd.com/read/38613332/time-trend-analysis-of-rare-cancer-incidence-2011-2018-nationwide-population-based-cancer-registries-in-japan
#12
JOURNAL ARTICLE
Hiromi Sugiyama, Manami Konda, Kumiko Saika, Tomohiro Matsuda
Rare cancers collectively account for a significant proportion of the overall cancer burden in Japan. We aimed to describe and examine the incidence of each rare cancer and the temporal changes using the internationally agreed rare cancer classification. Cancer cases registered in regional population-based cancer registries from 2011 to 2015 and the National Cancer Registry (NCR) from 2016 to 2018 were classified into 18 families, 68 Tier-1 cancer groupings, and 216 single cancer entities based on the RARECAREnet list...
April 13, 2024: Cancer Science
https://read.qxmd.com/read/38613253/pyroptotic-macrophages-promote-proliferation-and-chemotherapy-resistance-of-peripheral-t-cell-lymphoma-via-tlr4-signaling-pathway
#13
JOURNAL ARTICLE
Han Zhang, Liru Li, Zijian Zhang, Shiqi Gao, Mingzhe Yang, Wenjie Ma, Hongbin Li, Wenhui Zhao, Huike Yang, Yue Zhang, Shu Zhao
Peripheral T-cell lymphoma (PTCL) is a highly aggressive type of non-Hodgkin's lymphoma with a poor prognosis. Pyroptosis is a newly discovered procedural cell death mode, which has been implicated to occur in both tumor cells and immune cells. However, the occurrence and effect of pyroptosis on PTCL remain unclear. Here, we found that pyroptosis occurred in interstitial macrophages of PTCL rather than in tumor cells. In clinical specimens, macrophage pyroptosis was associated with a poor prognosis of PTCL...
April 13, 2024: Cancer Science
https://read.qxmd.com/read/38613239/ecm1-and-krt6a-are-involved-in-tumor-progression-and-chemoresistance-in-the-effect-of-dexamethasone-on-pancreatic-cancer
#14
JOURNAL ARTICLE
Yoshiki Shinomiya, Yusuke Kouchi, Sakurako Harada-Kagitani, Takayuki Ishige, Shigetsugu Takano, Masayuki Ohtsuka, Jun-Ichiro Ikeda, Takashi Kishimoto
Pancreatic ductal adenocarcinoma (PDAC) has a very poor prognosis. Neoadjuvant chemotherapy is an effective PDAC treatment option, but chemotherapy causes unfavorable side effects. Glucocorticoids (e.g., dexamethasone [DEX]) are administered to reduce side effects of chemotherapy for solid tumors, including pancreatic cancer. Glucocorticoids have both beneficial and detrimental effects, however. We investigated the functional changes and gene-expression profile alterations induced by DEX in PDAC cells. PDAC cells were treated with DEX, and the cell proliferation, migration, invasion, and chemosensitivity to gemcitabine (GEM) were evaluated...
April 13, 2024: Cancer Science
https://read.qxmd.com/read/38602182/antiapoptotic-pon2-expression-and-its-clinical-implications-in-locally-advanced-oral-squamous-cell-carcinoma
#15
JOURNAL ARTICLE
Mehta Vedant Kamal, Rama Rao Damerla, Preetiparna Parida, Sanjiban Chakrabarty, Mahadev Rao, Naveena An Kumar
Locally advanced oral squamous cell carcinoma poses a significant challenge in oncology due to its rising incidence and mortality rates. Despite therapeutic progress, understanding molecular intricacies is essential. This study explored the role of PON2, a multifunctional enzyme implicated in antiapoptotic mechanisms. Aberrant PON2 expression in oral cancers raises questions regarding its involvement in evading programmed cell death and treatment resistance. Patients with locally advanced disease were enrolled, and molecular analyses were undertaken on the collected tumor and normal tissues...
April 11, 2024: Cancer Science
https://read.qxmd.com/read/38594840/cytosolic-dna-sensor-aim2-promotes-kras-driven-lung-cancer-independent-of-inflammasomes
#16
JOURNAL ARTICLE
Mohammad Alanazi, Teresa Weng, Louise McLeod, Linden J Gearing, Julian A Smith, Beena Kumar, Mohamed I Saad, Brendan J Jenkins
Constitutively active KRAS mutations are among the major drivers of lung cancer, yet the identity of molecular co-operators of oncogenic KRAS in the lung remains ill-defined. The innate immune cytosolic DNA sensor and pattern recognition receptor (PRR) Absent-in-melanoma 2 (AIM2) is best known for its assembly of multiprotein inflammasome complexes and promoting an inflammatory response. Here, we define a role for AIM2, independent of inflammasomes, in KRAS-addicted lung adenocarcinoma (LAC). In genetically defined and experimentally induced (nicotine-derived nitrosamine ketone; NNK) LAC mouse models harboring the KrasG12D driver mutation, AIM2 was highly upregulated compared with other cytosolic DNA sensors and inflammasome-associated PRRs...
April 9, 2024: Cancer Science
https://read.qxmd.com/read/38590281/igsf3-is-a-homophilic-cell-adhesion-molecule-that-drives-lung-metastasis-of-melanoma-by-promoting-adhesion-to-vascular-endothelium
#17
JOURNAL ARTICLE
Yue Guo, Yutaka Kasai, Yuto Tanaka, Yuki Ohashi-Kumagai, Takeharu Sakamoto, Takeshi Ito, Yoshinori Murakami
The immunoglobulin superfamily (IgSF) is one of the largest families of cell-surface molecules involved in various cell-cell interactions, including cancer-stromal interactions. In this study, we undertook a comprehensive RT-PCR-based screening for IgSF molecules that promote experimental lung metastasis in mice. By comparing the expression of 325 genes encoding cell-surface IgSF molecules between mouse melanoma B16 cells and its highly metastatic subline, B16F10 cells, we found that expression of the immunoglobulin superfamily member 3 gene (Igsf3) was significantly enhanced in B16F10 cells than in B16 cells...
April 9, 2024: Cancer Science
https://read.qxmd.com/read/38590234/prognostic-effect-of-tcf1-cd8-t-cell-and-tox-cd8-t-cell-infiltration-in-lung-adenocarcinoma
#18
JOURNAL ARTICLE
Yao Wang, Lin Ma, Yu Chen, Wenhua Yun, Jinming Yu, Xiangjiao Meng
Recent studies have highlighted the pivotal roles of T cell transcription factors TCF-1 and TOX in modulating the immune response in cancer, with TCF-1 maintaining CD8+ T cell stemness and TOX promoting T cell exhaustion. The prognostic significance of these factors in lung adenocarcinoma (LUAD) remains a critical area of investigation. The retrospective study included 191 patients with LUAD who underwent surgery, of whom 83% were in stages II and III. These patients were divided into exploratory (n = 135) and validation (n = 56) groups based on the time of diagnosis...
April 9, 2024: Cancer Science
https://read.qxmd.com/read/38581120/a-new-tandem-repeat-enriched-lncrna-xloc_008672-promotes-gastric-carcinogenesis-by-regulating-g3bp1-expression
#19
JOURNAL ARTICLE
Li Li, Shijun Yu, Ning Dou, Xiao Wang, Yong Gao, Yandong Li
Aberrant expression of forkhead box transcription factor 1 (FOXM1) plays critical roles in a variety of human malignancies and predicts poor prognosis. However, little is known about the crosstalk between FOXM1 and long noncoding RNAs (lncRNAs) in tumorigenesis. The present study identifies a previously uncharacterized lncRNA XLOC_008672 in gastric cancer (GC), which is regulated by FOXM1 and possesses multiple copies of tandem repetitive sequences. LncRNA microarrays are used to screen differentially expressed lncRNAs in FOXM1 knockdown GC cells, and then the highest fold downregulation lncRNA XLOC_008672 is screened out...
April 5, 2024: Cancer Science
https://read.qxmd.com/read/38572526/decreased-risk-of-renal-cell-carcinoma-in-patients-with-type-2-diabetes-treated-with-sodium-glucose-cotransporter-2-inhibitors
#20
JOURNAL ARTICLE
Chun-Huei Chiu, Wei-Yao Wang, Hung-Yi Chen, Pei-Lun Liao, Gwo-Ping Jong, Tsung-Yuan Yang
Patients with type 2 diabetes (T2D) are at a higher risk of developing renal cell carcinoma (RCC) than the general population. In vitro and in vivo investigations of the effects of sodium glucose cotransporter-2 inhibitors (SGLT2I) have shown a significantly reduced risk of RCC. However, the impact of these drugs on the incidence of RCC in the human population is unclear. This study aimed to examine the association between SGLT2I use and RCC risk in patients with T2D. We undertook a nationwide retrospective cohort study using the Health and Welfare Data Science Center database (2016-2020)...
April 4, 2024: Cancer Science
journal
journal
40398
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.